Literature DB >> 31352589

Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments.

Kristen M Beck1, Gerami D Seitzman2, Eric J Yang3, Isabelle M Sanchez3, Wilson Liao3.   

Abstract

Treatments used for managing atopic dermatitis (AD) may have adverse ocular effects that permanently affect vision. The objective of this review is to raise awareness among dermatologists regarding the potential ocular adverse effects of various AD therapies, including corticosteroids, calcineurin inhibitors, an interleukin-4 receptor α (IL-4Rα) antagonist, and phototherapy. Pertinent potential short- and long-term risks of these therapies include elevations in intraocular pressure from use of topical corticosteroids and conjunctivitis from use of dupilumab. Since some of these adverse effects may not exhibit symptomatology until permanent vision impairment occurs, it is important for dermatologists to understand these risks and proactively ensure their patients are receiving appropriate measures to prevent them.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31352589     DOI: 10.1007/s40257-019-00465-3

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  4 in total

1.  Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.

Authors:  Roselie E Achten; Chantal Van Luijk; Lisa Van der Rijst; Daphne Bakker; Lotte Spekhorst; Nicolaas Zuithoff; Marie Schuttelaar; Geertruida Romeijn; Angelique Voorberg; Marijke Kamsteeg; Inge Haeck; Marlies De Graaf; Judith Thijs; Joke De Boer; Marjolein De Bruin-Weller
Journal:  Acta Derm Venereol       Date:  2022-03-11       Impact factor: 3.875

Review 2.  Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP).

Authors:  Elena Galli; Anna Belloni Fortina; Giampaolo Ricci; Nunzia Maiello; Iria Neri; Ermanno Baldo; Irene Berti; Domenico Bonamonte; Lucetta Capra; Elena Carboni; Rossella Carello; Francesca Caroppo; Giovanni Cavagni; Iolanda Chinellato; Francesca Cipriani; Pasquale Comberiati; Andrea Diociaiuti; Vito Di Lernia; Marzia Duse; Cesare Filippeschi; Arianna Giannetti; Mattia Giovannini; Amelia Licari; Gian Luigi Marseglia; Manuela Pace; Annalisa Patrizi; Giovanni Battista Pajno; Diego Peroni; Alberto Villani; Lawrence Eichenfield
Journal:  Ital J Pediatr       Date:  2022-06-14       Impact factor: 3.288

Review 3.  A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.

Authors:  Gaurav Agnihotri; Katherine Shi; Peter A Lio
Journal:  Drugs R D       Date:  2019-12

4.  Irreversible Bilateral Cicatricial Keratoconjunctivitis after Dupilumab Therapy.

Authors:  Minh T Nguyen; Mai Tsukikawa; Whitney Lomazow; Michele Lee
Journal:  Case Rep Ophthalmol       Date:  2022-08-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.